NCT06519448View on ClinicalTrials.gov

Reducing Non-Alcoholic Steatohepatitis

NAEnrolling by invitationINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Non-alcoholic SteatohepatitisLiver DiseasesDiabetes Mellitus, Type 2Fibrosis, Liver
Interventions
DRUG

Empagliflozin 10 miligrams (mg)

Use of empagliflozin 10 mg daily for 12 months.

Trial Locations (1)

16902

Central Military Hospital, Prague

All Listed Sponsors
lead

Military University Hospital, Prague

OTHER